Beauty Industry Bulletins

InMode (NASDAQ: INMD) price target raised by Robert W. Baird to USD 80.00

InMode (NASDAQ: INMD) had raised its price target on Robert W. Baird from USD 62.00 to USD 80.00 in a research report published on Wednesday, reports The Fly. The company currently has an “outperform” rating on the healthcare company’s stock. Robert W. Baird’s price target would indicate a potential downward trend of 3.03% from the current price of the stock.

A number of other analysts have also released reports on the company. Needham & Company LLC cut its target price on InMode to $ 103.00 and issued a “buy” rating for the stock in a research note on Tuesday. Canaccord Genuity raised its price target for InMode from USD 60.00 to USD 80.00 and rated the stock as a “Buy” in a report on Wednesday. Barclays raised its target price on InMode from $ 60.00 to $ 85.00 and rated the stock as “overweight” in a research report on Wednesday. Finally, TheStreet downgraded InMode from a “b-” rating to a “c” rating in a research note on Friday October 1. One analyst has rated the stock with a hold rating and five with a buy rating. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $ 71.58.

NASDAQ: INMD rose $ 7.06 during Wednesday’s trading hours to hit $ 82.50. The company’s share had a trading volume of 57,057 shares compared to an average volume of 1,600,026 shares. The stock has a fifty-day simple moving average of $ 68.00 and a 200-day simple moving average of $ 52.82. InMode has a twelve month low of $ 18.02 and a twelve month high of $ 90.00. The company has a market cap of $ 5.28 billion, a P / E of 54.75, and a beta of 1.65.

InMode (NASDAQ: INMD) last released its quarterly earnings data on Wednesday, July 28th. The healthcare company reported $ 0.51 EPS for the quarter, beating Thomson Reuters’ consensus estimate of $ 0.24 by $ 0.27. InMode had a return on equity of 45.87% and a net margin of 44.34%. The company had sales of $ 87.33 million for the quarter.

(Advertisement)

The demand for plant-based foods is blazing hot, with a potential of $ 85 billion.

A number of major investors have recently changed their positions in INMD. Arkadios Wealth Advisors increased its stake in InMode by 83.2% in the second quarter. Arkadios Wealth Advisors now owns 348 shares in the healthcare company valued at $ 32,000 after buying an additional 158 shares during the period. TFC Financial Management acquired a new stake in InMode stock valued at approximately $ 43,000 in the second quarter. O Shaughnessy Asset Management LLC took a new position in InMode stock valued at approximately $ 33,000 in the first quarter. Lazard Asset Management LLC took a new position in shares of InMode valued at approximately $ 57,000 in the second quarter. Finally, Macquarie Group Ltd. their position in InMode increased 74.8% in the second quarter. Macquarie Group Ltd. now owns 855 shares of the healthcare company valued at $ 81,000 after buying an additional 366 shares last quarter.

InMode company profile

InMode Ltd. designs, develops, manufactures and markets minimally invasive aesthetic medical devices based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally invasive aesthetic medical products for various interventions, such as liposuction with simultaneous skin tightening, body and face contouring and ablative skin rejuvenation treatments.

Further reading: What are the risks of holding government bonds?

The Fly logo

Analyst Recommendations for InMode (NASDAQ: INMD)

This instant news alert was generated through narrative science technology and financial data from MarketBeat to provide readers with the fastest, most accurate coverage. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $ 1,000 in InMode now?

Before you consider InMode, this is what you should hear.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their customers to buy now, before the wider market takes hold … and InMode wasn’t on the list.

While InMode is currently rated “Buy” by analysts, top-rated analysts think these five stocks are better buys.

Check out the 5 stocks here

Comments are closed.